ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1491

Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjögren’s Syndrome Patients

Alessia Gallo1, Mayank Tandon1, Stamatina Danielides2, Ana Paola Cotrim3 and Ilias Alevizos4, 1Sjogren's Clinic, NIDCR, Bethesda, MD, 2Nidcr, NIH, Bethesda, MD, 3NIDCR, NIH, Bethesda, MD, 4Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: MicroRNA and Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Sjögren’s syndrome is a complex autoimmune disease of the salivary gland with an unknown etiology, so a thorough characterization of the transcriptome would facilitate our understanding of the disease. We used ultra-deep sequencing of small RNAs of human salivary glands to identify and discover novel miRNA sequences that may play a role in the disease and validated the presence of those novel miRNAs in other human tissues.

Methods:

Total RNA was isolated from minor salivary glands of healthy volunteers and patients with either high or low salivary flow. The sequencing was performed on the SOLiD platform (Applied Biosystems), using their Small RNA Expression Kit protocol, which selectively enriches small RNAs (< 300 bp).  These sequencing reads were mapped to three different databases, and if reads matched to any of the databases were removed. The unmapped sequences were subsequently examined for other characteristics of microRNA, such as the loop formation of the premicroRNA, with the web-based algorithm miRanalyzer. The novel sequences that possessed the characteristics of microRNAs were subsequently validated with custom desgined TaqMan probes, in several human tissue (bladder, brain, lung, ovary, kidney, adipose tissue, spleen, colon, placenta, thymus, liver and testes total RNA) and a new cohort of minor salivary gland RNA from healthy volunteer and Sjögren’s syndrome patients).

Results:

There were 121,148 (patient – high flow), 52,568 (patient – low flow), and 174,482 (Healthy Volunteer) unique reads that matched to the human genome. These genome-matched reads generated a total of 222 predicted mature miRNAs. Following the selection process, we identified 44 candidates. Of these candidates, 16 had variable expression among the different human tissues and some of them were differentially expressed between Sjogren’s syndrome and healthy control salivary glands.

Conclusion:

Sequencing small RNAs in the salivary glands has not been extensively and systematically performed. Our work not only identified novel microRNAs, but also identified differentially expressed microRNAs between healthy controls and Sjögren’s syndrome patients


Disclosure:

A. Gallo,
None;

M. Tandon,
None;

S. Danielides,
None;

A. P. Cotrim,
None;

I. Alevizos,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-and-validation-of-novel-micrornas-in-minor-salivary-glands-of-sjogrens-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology